| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/CCO.0B013E32801173EA |
| P698 | PubMed publication ID | 17133107 |
| P2093 | author name string | Douglas W Ball | |
| P2860 | cites work | The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins | Q24293701 |
| Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase | Q24803451 | ||
| P433 | issue | 1 | |
| P921 | main subject | thyroid cancer | Q826522 |
| P304 | page(s) | 18-23 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Current Opinion in Oncology | Q1909046 |
| P1476 | title | Medullary thyroid cancer: therapeutic targets and molecular markers | |
| P478 | volume | 19 |
| Q39002421 | A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2. |
| Q34153520 | A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo |
| Q34029020 | Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. |
| Q94367553 | Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation |
| Q38233319 | Cabozantinib: a review of its use in patients with medullary thyroid cancer |
| Q39480385 | Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. |
| Q37988566 | Differentiated thyroid cancers: a comprehensive review of novel targeted therapies |
| Q36765871 | Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report |
| Q64101533 | Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma in the Same Patient as a Collision Tumour |
| Q36142421 | Medullary thyroid carcinoma: The third most common thyroid cancer reviewed |
| Q34635409 | Medullary thyroid carcinoma: surgical treatment advances. |
| Q33557376 | Medullary thyroid carcinoma: targeted therapies and future directions |
| Q40847701 | Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen |
| Q55564375 | Molecular Therapies in Thyroid Cancer. |
| Q37118544 | Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. |
| Q37238757 | New developments in the diagnosis and treatment of thyroid cancer |
| Q37624735 | Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development? |
| Q38848857 | Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line. |
| Q43891433 | Prognostic and predictive markers in medullary thyroid carcinoma |
| Q37134454 | RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer |
| Q37331749 | Safe incorporation of new technologies in thyroid surgery. |
| Q42945757 | Simultaneous medullary and papillary thyroid cancer: two case reports. |
| Q43833248 | Simultaneous medullary carcinoma, papillary carcinoma and granulomatous inflammation of the thyroid |
| Q43285102 | Sorafenib induces partial response in metastatic medullary thyroid carcinoma |
| Q37533403 | Synchronous multifocal medullary and papillary thyroid microcarcinoma detected by elastography |
| Q37860132 | Targeted therapies for thyroid tumors. |
| Q36164034 | The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer |
| Q36508942 | The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. |
| Q36037051 | Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer |
| Q33984845 | Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer |
| Q38039483 | Vandetanib: a guide to its use in advanced medullary thyroid cancer |
| Q38020194 | Vandetanib: in medullary thyroid cancer |
| Q30428632 | XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. |
Search more.